Roche has released positive phase 2 data for its proposed novel anti–vascular endothelial growth factor and anti–angiopoietin-2 bispecific antibody, RG7716.
Roche has released positive phase 2 data for its proposed novel anti—vascular endothelial growth factor (anti-VEGF) and anti–angiopoietin-2 bispecific antibody, RG7716. The proposed drug, says Roche, is the first bispecific antibody designed specifically for the treatment of retinal eye diseases. The data show that RG7716 resulted in clinically meaningful, statistically significant improvements in visual acuity gains compared to Roche’s ranibizumab (Lucentis) alone.
The phase 2 BOULEVARD trial—a prospective, randomized, comparator-controlled, double-masked, multicenter, 3-arm study, assessed 2 doses of RG7716, 1.5 mg and 6 mg (given monthly for 20 weeks), versus ranibizumab, in 229 patients with diabetic macular edema.
The study met its primary endpoint: demonstrating a significant improvement in adjusted Best Corrected Visual Acuity at week 24 for RG7716 versus ranibizumab in treatment-naïve patients. The 6-mg dose of the investigational drug resulted in an adjusted mean improvement of 13.9 chart letters from baseline, compared with 10.3 letters in patients treated with 0.3 mg of ranibizumab. RG7716 was also well tolerated, with no new safety signals observed. The data were presented at Angiogenesis, Exudation, and Degeneration 2018, a medical symposium presented by Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine.
Despite these results, some analysts see little reason for excitement about the proposed novel drug; Fierce Pharma reports that analyst Geoffrey Porges of Leerink Partners told clients that the trial results were “somewhat lackluster,” and that RG7716 and brolucizumab—an anti-VEGF that Novartis said in 2017 had met its primary phase 3 endpoint of non-inferiority versus Regeneron’s aflibercept (Eylea) in patients with neovascular age-related macular degeneration—had no “clear advantages” over existing anti-VEGF options.
However, those existing drugs face encroaching biosimilar competition. In January 2018, Momenta and Mylan announced that they will begin a pivotal clinical trial of M710, a proposed aflibercept biosimilar, and German drug maker Formycon reports that it is in preclinical development with its own aflibercept molecule, FYB203. Ranibizumab, meanwhile, faces challenges from Formycon’s FYB201 and Samsung Bioepis’ SB11, both of which are in phase 3 development. Finally, the off-label use of Avastin (bevacizumab), an anti-VEGF approved for cancer indications only, has been steadily increasing in the treatment of eye diseases, and the upcoming launch of a biosimilar bevacizumab (the FDA-approved Mvasi), is likely to perpetuate this trend.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
September 14th 2024A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.
BioRationality: FDA Clarification Provides New Indications and Process Change for Biosimilars
September 9th 2024Sarfaraz K. Niazi, PhD, explains the FDA's new guidelines on post-approval changes for biosimilars, emphasizing the processes for reporting modifications, comparability assessments, and the potential for biosimilars to introduce new indications or formulation changes, which could significantly impact their market competitiveness and accessibility.